EMERGENT BIOSOLUTIONS INC. Share-based Payment Arrangement, Expense
EMERGENT BIOSOLUTIONS INC. (EBS) reported Share-based Payment Arrangement, Expense of $6.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense for the quarter ending 2026-06-30 was $6.90M, a 50.00% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense for the quarter ending 2026-03-31 was $1.90M, a 26.67% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense for the quarter ending 2025-12-31 was $5.30M, a 23.26% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense for the quarter ending 2025-09-30 was $4.80M, a 108.70% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense for fiscal 2025 was $16.20M, a 10.00% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense for fiscal 2024 was $18.00M, a 22.08% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense for fiscal 2023 was $23.10M, a 48.78% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. share-based payment arrangement, expense for fiscal 2022 was $45.10M, a 6.37% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month | Share-based Payment Arrangement, Expense 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $6.90M 10-Q · filed 2026-08-06 | $8.80M 10-Q · filed 2026-08-06 | $14.10M derived: sum of 3 quarters · filed 2026-08-06 | $18.90M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $1.90M 10-Q · filed 2026-05-01 | $7.20M derived: sum of 2 quarters · filed 2026-05-01 | $12.00M derived: sum of 3 quarters · filed 2026-05-01 | $16.60M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $5.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $10.10M derived: sum of 2 quarters · filed 2026-02-27 | $14.70M derived: sum of 3 quarters · filed 2026-08-06 | $16.20M 10-K · filed 2026-02-27 | |
| 2025-09-30 | $4.80M 10-Q · filed 2025-10-30 | $9.40M derived: sum of 2 quarters · filed 2026-08-06 | $10.90M 10-Q · filed 2025-10-30 | $15.20M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $4.60M 10-Q · filed 2026-08-06 | $6.10M 10-Q · filed 2026-08-06 | $10.40M derived: sum of 3 quarters · filed 2026-08-06 | $12.70M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $1.50M 10-Q · filed 2026-05-01 | $5.80M derived: sum of 2 quarters · filed 2026-05-01 | $8.10M derived: sum of 3 quarters · filed 2026-05-01 | $13.60M derived: sum of 4 quarters · filed 2026-05-01 | |
| 2024-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $6.60M derived: sum of 2 quarters · filed 2026-02-27 | $12.10M derived: sum of 3 quarters · filed 2026-02-27 | $18.00M 10-K · filed 2026-02-27 | |
| 2024-09-30 | $2.30M 10-Q · filed 2025-10-30 | $7.80M derived: sum of 2 quarters · filed 2025-10-30 | $13.70M 10-Q · filed 2025-10-30 | $17.70M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-06-30 | $5.50M 10-Q · filed 2025-08-07 | $11.40M 10-Q · filed 2025-08-07 | $15.40M derived: sum of 3 quarters · filed 2026-02-27 | $19.40M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2024-03-31 | $5.90M 10-Q · filed 2025-05-08 | $9.90M derived: sum of 2 quarters · filed 2026-02-27 | $13.90M derived: sum of 3 quarters · filed 2026-02-27 | $22.20M derived: sum of 4 quarters · filed 2026-02-27 | |
| 2023-12-31 | $4.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $8.00M derived: sum of 2 quarters · filed 2026-02-27 | $16.30M derived: sum of 3 quarters · filed 2026-02-27 | $23.10M 10-K · filed 2026-02-27 | |
| 2023-09-30 | $4.00M 10-Q · filed 2024-11-07 | $12.30M derived: sum of 2 quarters · filed 2024-11-07 | $19.10M 10-Q · filed 2024-11-07 | $30.80M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-06-30 | $8.30M 10-Q · filed 2024-08-07 | $15.10M 10-Q · filed 2024-08-07 | $26.80M derived: sum of 3 quarters · filed 2025-03-04 | $38.00M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2023-03-31 | $6.80M 10-Q · filed 2024-05-02 | $18.50M derived: sum of 2 quarters · filed 2025-03-04 | $29.70M derived: sum of 3 quarters · filed 2025-03-04 | $42.00M derived: sum of 4 quarters · filed 2025-03-04 | |
| 2022-12-31 | $11.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $22.90M derived: sum of 2 quarters · filed 2025-03-04 | $35.20M derived: sum of 3 quarters · filed 2025-03-04 | $45.10M 10-K · filed 2025-03-04 | |
| 2022-09-30 | $11.20M 10-Q · filed 2023-12-11 | $23.50M derived: sum of 2 quarters · filed 2023-12-11 | $33.40M 10-Q · filed 2023-12-11 | $43.50M derived: sum of 4 quarters · filed 2024-03-08 | |
| 2022-06-30 | $12.30M 10-Q · filed 2023-08-09 | $22.20M 10-Q · filed 2023-08-09 | $32.30M derived: sum of 3 quarters · filed 2024-03-08 | $42.70M derived: sum of 4 quarters · filed 2024-03-08 | |
| 2022-03-31 | $9.90M 10-Q · filed 2023-05-10 | $20.00M derived: sum of 2 quarters · filed 2024-03-08 | $30.40M derived: sum of 3 quarters · filed 2024-03-08 | $41.80M derived: sum of 4 quarters · filed 2024-03-08 | |
| 2021-12-31 | $10.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $20.50M derived: sum of 2 quarters · filed 2024-03-08 | $31.90M derived: sum of 3 quarters · filed 2024-03-08 | $42.40M 10-K · filed 2024-03-08 | |
| 2021-09-30 | $10.40M 10-Q · filed 2022-11-09 | $21.80M derived: sum of 2 quarters · filed 2022-11-09 | $32.30M 10-Q · filed 2022-11-09 | $43.10M derived: sum of 4 quarters · filed 2023-12-11 | |
| 2021-06-30 | $11.40M 10-Q · filed 2022-08-02 | $21.90M 10-Q · filed 2022-08-02 | $32.70M derived: sum of 3 quarters · filed 2023-12-11 | $42.70M derived: sum of 4 quarters · filed 2023-12-11 | |
| 2021-03-31 | $10.50M 10-Q · filed 2022-04-29 | $21.30M derived: sum of 2 quarters · filed 2023-12-11 | $31.30M derived: sum of 3 quarters · filed 2023-12-11 | $55.70M derived: sum of 4 quarters · filed 2023-12-11 | |
| 2020-12-31 | $10.80M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $20.80M derived: sum of 2 quarters · filed 2023-12-11 | $45.20M derived: sum of 3 quarters · filed 2023-12-11 | $51.80M 10-K/A · filed 2023-12-11 | $51.00M 10-K · filed 2021-02-19 |
| 2020-09-30 | $10.00M 10-Q · filed 2021-11-05 | $34.40M derived: sum of 2 quarters · filed 2021-11-05 | $41.00M 10-Q · filed 2021-11-05 | $46.70M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-06-30 | $24.40M 10-Q · filed 2021-07-30 | $31.00M 10-Q · filed 2021-07-30 | $36.70M derived: sum of 3 quarters · filed 2022-02-25 | $42.80M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2020-03-31 | $6.60M 10-Q · filed 2021-04-30 | $12.30M derived: sum of 2 quarters · filed 2022-02-25 | $18.40M derived: sum of 3 quarters · filed 2022-02-25 | $26.50M derived: sum of 4 quarters · filed 2022-02-25 | |
| 2019-12-31 | $5.70M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $11.80M derived: sum of 2 quarters · filed 2022-02-25 | $19.90M derived: sum of 3 quarters · filed 2022-02-25 | $26.70M 10-K · filed 2022-02-25 | |
| 2019-09-30 | $6.10M 10-Q · filed 2020-11-06 | $14.20M derived: sum of 2 quarters · filed 2020-11-06 | $21.00M 10-Q · filed 2020-11-06 | ||
| 2019-06-30 | $8.10M 10-Q · filed 2020-07-31 | $14.90M 10-Q · filed 2020-07-31 | |||
| 2018-12-31 | $23.20M 10-K · filed 2021-02-19 | ||||
| 2017-12-31 | $15.20M 10-K · filed 2020-02-25 | $15.21M 10-K · filed 2018-02-23 | |||
| 2016-12-31 | $18.50M 10-K · filed 2019-02-22 | $18.48M 10-K · filed 2017-02-28 | |||
| 2015-12-31 | $15.85M 10-K · filed 2018-02-23 | ||||
| 2014-12-31 | $12.83M 10-K · filed 2017-02-28 | ||||
| 2013-12-31 | $11.24M 10-K · filed 2016-02-29 | $11.11M 10-K · filed 2014-03-10 | |||
| 2012-12-31 | $11.12M 10-K · filed 2015-03-09 | ||||
| 2011-12-31 | $10.74M 10-K · filed 2014-03-10 | ||||
| 2010-12-31 | $7.06M 10-K · filed 2013-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |